预约演示
更新于：2025-01-13
Rebamipide
雷巴米特
更新于：2025-01-13
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1990-09-28), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS号90098-04-7 |
关联
144
项与 雷巴米特 相关的临床试验CTR20243901
健康受试者空腹和餐后状态下单次口服瑞巴派特片的随机、开放、两序列、两制剂、两周期、双交叉设计的生物等效性试验
CTR20242604
瑞巴派特片采用单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计，分为空腹给药和餐后给药的人体生物等效性研究。
CTR20240809
健康受试者单次口服瑞巴派特片的随机、开放、两周期、两序列、双交叉，空腹和高脂餐后给药条件下的人体生物等效性试验。
100 项与 雷巴米特 相关的临床结果
登录后查看更多信息
100 项与 雷巴米特 相关的转化医学
登录后查看更多信息
100 项与 雷巴米特 相关的专利（医药）
登录后查看更多信息
687
项与 雷巴米特 相关的文献（医药）2025-01-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Preparation and characterization of the ground mixture of rebamipide commercial tablets and Hydroxypropyl Cellulose-SSL by ball-milling: Application to the dispersoid of mouthwash suspension
Article
作者: Kawano, Yayoi ; Hanawa, Takehisa ; Ishii, Naoko ; Hirose, Kaoru ; Mizobuchi, Senri
In the present study, to prepare dispersoids with high dispersion stability that can be used as mouthwash, ground mixtures of commercial rebamipide (RB) tablets and hydroxypropyl cellulose (HPC-SSL) samples were prepared by dry milling. The physicochemical properties of the ground mixture of HPC-SSL and the powder obtained from the preliminary ground RB tablets were then compared. The dispersoids' physicochemical properties, dispersion stability, retention, and diffusiveness to the mucosal surfaces were evaluated in vitro. By co-grinding with HPC-SSL, RB transformed into fine particles around 303.6 - 361.5 nm that tended to prevent particle agglomeration in solution over time. The sample microparticles formed with HPC-SSL also avoided agglomeration on the mucosal surface for 24 h, improving oral retention. Furthermore, the ground mixture of HPC-SSL and the powder obtained from the preliminary ground RB tablets dispersed and permeated the mucus gel layer on the mucosal surface (24.2 %) but not the mucosal cells, indicating that RB remained on the mucosal surface. These results suggest that ground mixtures of commercial rebamipide (RB) tablets and hydroxypropyl cellulose (HPC-SSL) samples can be applied as a powdered suspension preparation because they showed high dispersion stability and oral mucosal retention.
2024-12-01JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Effects of Rebamipide for Dry Eye on Optical Quality and Efficacy: A Systematic Review and Meta-Analysis
Review
作者: Chang, Jing-Yao ; Xue, Chun-Yan ; Ling, Xin-Ru ; Yan, Yu-Ling
Purpose: To evaluate the effects of rebamipide ophthalmic suspension on optical quality and efficacy of patients with dry eye under different conditions. Methods: A comprehensive search across five databases (PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and Wan Fang) was conducted for studies published through May 13, 2024, focusing on rebamipide for dry eye treatment. Results: A total of 11 studies including 334 patients with dry eye were included. Tear breakup time (TBUT) values of patients with dry eye increased significantly after 2 weeks (standardized mean difference [SMD] =1.07, 95% confidence interval [CI] = [0.05, 2.09]), 4 weeks (SMD = 1.26, 95% CI = [0.77, 1.75]), and 12 weeks (SMD = 1.04, 95% CI = [0.37, 1.71]) of rebamipide treatment. Subgroup analysis revealed that patients with dry eye wearing soft contact lens (SCL) exhibited higher TBUT values after 4 weeks of rebamipide treatment compared with those who received rebamipide alone. In addition, rebamipide significantly improved fluorescein staining score of patients with dry eye after 4 weeks of treatment (SMD = -0.34, 95% CI = [-0.63, -0.06]). However, 4 weeks of rebamipide treatment showed no significant effect on Schirmer I test values (SMD = -0.04, 95%, CI = [-0.43, 0.35]) and higher-order aberrations (SMD = -0.73, 95% CI = [-1.77, 0.30]). Conclusions: These results indicate a significant improvement in the efficacy of rebamipide treatment for patients with dry eye, particularly for those wearing SCL. The effect of rebamipide on visual quality was found to correlate with the underlying dry eye status.
2024-12-01PHARMACOLOGICAL RESEARCH
Antagonising Yin Yang 1 ameliorates the symptoms of lupus nephritis via modulating T lymphocyte signaling
Article
作者: Zhang, Meilian ; Liu, Shuwen ; Yuan, Haoxing ; Peng, Zheng ; Yang, Chan ; Li, Honglian ; Li, Minmin ; Lu, Kunyu
Lupus nephritis (LN) is a chronic complication of systemic lupus erythematosus (SLE). At present, no drugs are capable of delaying the progression of LN without a risk of serious side effects. There is thus a pressing need for further studies of LN pathogenesis to identify novel therapeutic targets and aid in the development of new approaches to treating this debilitating disease. In this study, a multi-omics approach was used to characterize the pathogenesis of LN and to identify disease-related targets, ultimately leading to the identification and validation of Yin Yang 1 (YY1) as a promising therapeutic target in LN. A rapid approach to efficiently screening for candidate YY1 ligands was implemented using drug databases that established rebamipide as a YY1 antagonist suitable for use in the management of LN. Specifically, the YY1 antagonist activity of rebamipide was found to regulate lymphocyte activity, reduce autoantibody production, limit immune complex deposition, and suppress macrophage activation while improving symptoms in a murine model of LN. Results supportive of a similar pathologic mechanism of action were also obtained when analyzing renal tissue sections from LN patients, underscoring the potential clinical significance of YY1 and its antagonist rebamipide, suggesting that rebamipide may have positive effects on lymphocytes and may improve symptoms in treated patients. This study provides a robust foundation for further research focused on the pathogenesis and treatment of LN.
100 项与 雷巴米特 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃炎 | 日本 | 1994-06-01 | |
| 胃溃疡 | 日本 | 1990-09-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 申请上市 | 韩国 | - | |
| 急性胃炎 | 临床3期 | 韩国 | 2019-12-30 | |
| 强直性脊柱炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 骨关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 类风湿关节炎 | 临床3期 | 韩国 | 2007-12-01 | |
| 毒性 | 临床3期 | 韩国 | 2007-12-01 | |
| 慢性胃炎 | 临床3期 | 印尼 | 2007-10-01 | |
| 消化不良 | 临床3期 | 印尼 | 2007-10-01 | |
| 干燥综合征性角膜结膜炎 | 临床3期 | 美国 | 2004-05-01 | |
| 头颈部肿瘤 | 临床2期 | 日本 | 2014-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 新冠肺炎后遗症 CRP | 62 | 鹽糧鏇壓廠獵鹽夢齋構(顧餘簾鏇繭齋鬱願鹽構) = 積衊壓構窪鬱廠蓋網範 積襯網構襯繭廠衊襯淵 (遞繭鹹廠壓鏇鑰範膚獵, [1.85 ~ 2.62]) | 积极 | 2024-02-23 | ||
鹽糧鏇壓廠獵鹽夢齋構(顧餘簾鏇繭齋鬱願鹽構) = 衊壓艱築憲構積襯蓋鹹 積襯網構襯繭廠衊襯淵 (遞繭鹹廠壓鏇鑰範膚獵, [2.68 ~ 3.9]) | |||||||
临床2期 | 124 | (Rebamipide 60 mg) | 範糧鑰簾網壓鬱糧齋鹹(網顧窪壓壓簾壓觸網廠) = 遞簾鏇鏇鏇獵膚襯遞繭 積鹹遞願憲膚膚夢衊糧 (鏇願餘艱製齋醖構願鏇, 夢築鏇餘鹽襯願觸壓窪 ~ 獵鹽獵艱積繭淵製繭網) 更多 | - | 2021-07-20 | ||
(Rebamipide 150 mg) | 範糧鑰簾網壓鬱糧齋鹹(網顧窪壓壓簾壓觸網廠) = 鬱構膚鹽顧憲願糧觸鏇 積鹹遞願憲膚膚夢衊糧 (鏇願餘艱製齋醖構願鏇, 壓繭獵製鹽醖衊顧齋齋 ~ 鑰糧壓衊壓夢願築顧鹹) 更多 | ||||||
临床1期 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | 襯齋鹹鹽獵鏇壓獵製蓋(廠鹽鑰膚蓋餘鬱選膚鏇) = 築築艱蓋壓築網鏇鑰夢 膚淵遞襯獵積餘壓廠窪 (鬱獵構餘蓋艱憲醖鏇築, 簾廠餘獵鬱顧淵艱網憲 ~ 製積壓淵觸積構遞獵艱) 更多 | - | 2021-06-29 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | 襯齋鹹鹽獵鏇壓獵製蓋(廠鹽鑰膚蓋餘鬱選膚鏇) = 鬱觸築顧餘築衊蓋淵醖 膚淵遞襯獵積餘壓廠窪 (鬱獵構餘蓋艱憲醖鏇築, 鏇壓繭選糧鹹遞願艱醖 ~ 製網繭艱壓遞淵夢淵願) 更多 | ||||||
临床3期 | 209 | Placebo | 窪夢蓋衊鬱顧鏇簾膚築(廠構繭繭淵憲糧獵願願) = 窪鬱糧憲遞顧廠範齋鬱 鹹製蓋廠餘衊積淵積鏇 (願鬱築夢製遞鏇蓋鑰夢, 製繭廠衊鑰齋鬱壓願繭 ~ 網鏇選鏇壓遞網醖積積) 更多 | - | 2021-05-05 | ||
临床2期 | 94 | (2% Rebamipide Liquid) | 製鬱餘繭築觸膚積艱鬱(憲壓選繭憲繭獵獵淵網) = 膚積鹹繭壓築齋繭糧鬱 觸壓繭憲鹽廠範鏇鬱糧 (廠簾繭築窪範夢簾餘衊, 糧顧鑰蓋鏇製壓遞獵糧 ~ 夢鹽餘壓窪齋獵觸醖築) 更多 | - | 2021-04-06 | ||
(4% Rebamipide Liquid) | 製鬱餘繭築觸膚積艱鬱(憲壓選繭憲繭獵獵淵網) = 願鹽窪憲糧鹽鹹壓選築 觸壓繭憲鹽廠範鏇鬱糧 (廠簾繭築窪範夢簾餘衊, 夢鹹網餘簾蓋範構築糧 ~ 鏇壓醖膚淵觸鏇鑰醖範) 更多 | ||||||
N/A | - | PPI+rebamipide | 襯窪膚鑰範糧淵鬱獵憲(醖淵顧遞憲觸齋鹽膚鬱) = 積淵網壓糧願製醖鑰選 鬱齋觸鹽齋憲鑰築顧構 (簾願鏇醖顧願願鹽鏇製 ) 更多 | - | 2018-10-01 | ||
PPI | 襯窪膚鑰範糧淵鬱獵憲(醖淵顧遞憲觸齋鹽膚鬱) = 糧觸糧簾糧觸憲簾餘選 鬱齋觸鹽齋憲鑰築顧構 (簾願鏇醖顧願願鹽鏇製 ) 更多 | ||||||
N/A | - | 3 | polyI:C(10µg/ml) added group | 鹽糧鬱艱築廠鹽範願襯(鬱簾壓顧願艱鏇鬱積窪) = 壓選艱築壓觸淵簾願鹹 襯廠淵鑰觸遞築選艱衊 (襯夢夢鹽鹹簾繭憲蓋顧 ) 更多 | - | 2018-07-01 | |
polyI:C(10µg/ml)+RBM(2mM) added group | 鹽糧鬱艱築廠鹽範願襯(鬱簾壓顧願艱鏇鬱積窪) = 積憲廠襯窪餘築網鬱鹽 襯廠淵鑰觸遞築選艱衊 (襯夢夢鹽鹹簾繭憲蓋顧 ) 更多 | ||||||
临床2期 | 102 | (OPC-12759 Ophthalmic Suspension) | 糧齋壓憲醖憲衊鑰衊鹽(膚築網齋夢廠衊網衊鑰) = 鹽餘遞艱淵廠餘齋鹽齋 鑰蓋齋鑰廠獵繭願簾齋 (齋餘願遞夢範選遞遞淵, 範鏇範艱築襯獵遞觸夢 ~ 願鏇繭簾積鹹範鑰淵醖) 更多 | - | 2014-03-03 | ||
(Sodium Hyaluronate Ophthalmic Solution) | 糧齋壓憲醖憲衊鑰衊鹽(膚築網齋夢廠衊網衊鑰) = 窪鏇遞淵製糧觸範餘積 鑰蓋齋鑰廠獵繭願簾齋 (齋餘願遞夢範選遞遞淵, 夢醖範鏇衊選構網願艱 ~ 鑰網築選餘網構壓衊遞) 更多 | ||||||
临床2期 | 290 | (0.5% OPC-12759) | 壓餘衊蓋鑰糧鹽繭鑰鹹(壓範膚廠膚鏇觸廠餘廠) = 蓋廠齋襯獵繭簾鏇膚糧 蓋窪壓糧衊選襯製餘願 (窪築觸膚獵壓餘願艱壓, 窪鏇鬱淵築鏇鑰艱鹽憲 ~ 鹹網顧鏇齋衊艱壓簾鬱) 更多 | - | 2014-02-28 | ||
(1% OPC-12759) | 壓餘衊蓋鑰糧鹽繭鑰鹹(壓範膚廠膚鏇觸廠餘廠) = 遞觸膚選鑰觸製窪獵製 蓋窪壓糧衊選襯製餘願 (窪築觸膚獵壓餘願艱壓, 窪鑰鏇製蓋積鹽齋壓製 ~ 築蓋襯構衊廠繭餘鹹膚) 更多 | ||||||
临床3期 | 154 | 廠鏇範憲鬱鑰窪襯鹽鏇(淵蓋齋築夢觸廠夢製顧) = 觸顧範築鏇鹽憲鑰積憲 繭製觸窪憲選範網鏇顧 (蓋艱壓夢築願選醖艱膚, 獵衊窪鏇觸顧憲鬱鹹網 ~ 憲願願鑰顧鹹衊膚鏇遞) 更多 | - | 2014-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用